DocGo

DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services and Mobile Health Solutions. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DocGo reports stellar 2022 performance and outlines growth strategies

DocGo's strong financial performance in 2022, coupled with robust guidance for 2023 and strategic operational initiatives, positions the company for continued growth and profitability.
While challenges like managing PHE impacts and transitioning to leased hour contracts exist, DocGo's proactive approach and operational strengths provide a solid foundation for addressing these hurdles.
With a focus on optimizing operations, pursuing growth opportunities, and leveraging its financial resources effectively, DocGo is poised to capitalize on market opportunities and deliver value to stakeholders.

DocGo reports Q1 revenue growth amidst margin challenges and future opportunities

DocGo's Q1 2023 performance showcased revenue growth and margin challenges, with a focus on improving margins through normalization initiatives.
Strengths include strong revenue guidance, significant contract opportunities, and partnerships driving backlog growth and revenue diversification.
Challenges stem from replacing high-margin COVID revenue, startup costs impacting margins, and negative cash flow in Q1 2023.
Opportunities lie in future revenue growth from new contracts, RPM services, public-private partnerships, and potential contract wins from upcoming RFPs.

DocGo (DCGO) reports stellar Q2 results, raises full-year guidance

DocGo's Q2 2023 showcased exceptional financial performance, with revenue and EBITDA growth exceeding expectations, underpinned by strong operational metrics and strategic decisions.
While facing challenges in backlog conversion and margin improvements, the company's focus on scalability, employee satisfaction, and market expansion positions it well for future growth.
Opportunities in new geographies, Remote Patient Monitoring integration, and transportation segment enhancements provide avenues for sustained revenue growth and operational excellence.

DocGo reports record Q3 revenue, eyes growth in commercial sector

DocGo's Q3 performance reflects strong revenue growth and improved EBITDA margins, driven by the success of Mobile Health and Transportation Services. While facing challenges with working capital and payment delays, the company is focused on catching up by year-end.
The company's strengths in contract performance, revenue guidance increase, and backlog diversification position it well for future growth. DocGo's strategic focus on commercial business expansion and customer experience enhancement aligns with its growth objectives.

DocGo reports record Q4 earnings, eyes growth in healthcare

DocGo delivered exceptional financial results in Q4 2023, showcasing robust revenue growth and profitability, driven by operational excellence and strategic investments.
While facing margin and cost challenges, the company's focus on growth, value-based care agreements, and revenue diversification positions it well for future success and market expansion.
With a strong cash position, revised revenue guidance, and proactive pursuit of new partnerships, DocGo is poised to capitalize on growth opportunities and navigate challenges effectively.
The company's commitment to transforming healthcare delivery and gratitude towards its staff underscore a resilient corporate culture and a dedication to driving positive impact in the industry.

DocGo reports robust Q1 earnings, eyes growth through unique care model

DocGo's Q1 2024 performance was strong, marked by revenue growth, improved margins, and profitability.
While facing challenges like revenue fluctuations and working capital pressures, the company is well-positioned for growth.
Opportunities lie in becoming a primary care provider, monetization strategies, and market differentiation through quality care.
Overall, DocGo's financial stability, growth plans, and unique service offerings position them for future success in the healthcare sector.

DocGo excels in Q2 2024, sets sights on clinical innovation

DocGo's Q2 2024 performance reflects financial strength and strategic advancements in clinical expertise and service expansion.
While facing challenges in meeting ambitious care gap closure targets, the company is well-positioned for growth.
Leveraging opportunities in mobile healthcare services and clinical program development can drive future success for DocGo.

DocGo reports robust Q3 earnings, eyes growth in migrant-related work

DocGo's Q3 2024 earnings call showcased strong financial performance, operational efficiency, and positive outlook for future revenue and cash flow.
While challenges such as revenue balancing and margin expectations were noted, opportunities for growth through migrant-related work and care programs were highlighted.
Overall, DocGo's performance and strategic direction position the company well for continued success and expansion in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services, Mobile Health Solutions, and Corporate. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The Corporate segment consists of information technology expenses. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.

RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--Rack Store proudly announces that the Southern California based company has secured more than 100 material handling dealers and customers nationwide.

Rack Store Secures Over 100 Material Handling Dealers Nationwide

NEW YORK--(BUSINESS WIRE)--New York City FC and DocGo (Nasdaq: DCGO), a leading global provider of technology-enabled mobile health services, today announced a new partnership, making Ambulnz by DocGo an Official Partner of New York City FC. Together, the two organizations will work collaboratively to empower healthier lives through soccer. As part of the partnership, Ambulnz will provide event medical services at New York City FC events and community initiatives. Ambulnz's brand will also be f.

DocGo Becomes Official Partner of New York City Football Club

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the following members of DocGo's leadership have recently purchased shares on the open market, as follows: - Norman Rosenberg, DocGo CFO, purchased a total of 10,000 shares of DocGo's common stock on March 14, 2024 at an average price of $3.61 per share. - Steven Katz, director and incoming Chair of the Board (to be effective Apri.

DocGo Leadership Purchase Shares in Open Market

DocGo stock receives a buy rating due to attractive upside potential and commendable execution demonstrated by management. Recent results show strong revenue growth and margin expansion, driven by steady contracts and growth in trip volumes and average price. Management's positive commentary, impressive pipeline, and plans for RFP submissions in FY24 indicate continued momentum and cross-sell success.

DocGo: Upside Remains Attractive After Share Price Decline

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that as of March 12, 2024, it has repurchased a total of 1.25 million shares of its common stock at an average of $3.88 per share under its share repurchase program announced on January 31, 2024 (the “Repurchase Program”). Pursuant to the Repurchase Program, DocGo is authorized to purchase up to $36 million of its common stock during a.

DocGo Announces Repurchases of Common Stock and Adoption of 10b5-1 Trading Plan for Share Repurchase Program

DocGo, Inc. (DCGO) Q4 2023 Earnings Call Transcript

DocGo Inc. (DCGO) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.11 per share a year ago.

DocGo Inc. (DCGO) Q4 Earnings Lag Estimates

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services in 30 states and the UK, today announced financial and operating results for the quarter and year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Total revenues for the fourth quarter of 2023 were $199.2 million, compared to $108.8 million in the fourth quarter of 2022, an increase of 83%. Gross margin for the fourth quarter of 2023 w.

DocGo Announces Record Fourth Quarter and Full-Year 2023 Results

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO), a leading provider of technology-enabled mobile health services, today announced the addition of two senior leaders bringing significant experience in large-scale public health program management and value-based care partnerships with health plans. Yong Kim has joined as Vice President of Health Plan Partnerships from his most recent role leading business operations and strategy for CVS Health's population health and care management programs.

DocGo Senior Leadership Hires Deepen Public Health, Value-based Care Experience

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the markets close on Wednesday, February 28, 2024. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Wednesday, February 28, 2024 5:0.

DocGo to Announce Fourth Quarter and Full Year 2023 Results on Wednesday, February 28, 2024

NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or the "Company") (NASDAQ: DCGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DocGo Inc. - DCGO

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO), a leading provider of technology-enabled mobile health services, announced today that management will be participating in the following investor conferences in February and March: BTIG at Snowbird – The 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 13-14, 2024 – 1x1 investor meetings, contact your BTIG representative for additional information. TD Cowen 44th Annual Health Care Conference Ma.

DocGo Announces Participation at Two Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that its Board of Directors has approved a new share repurchase program pursuant to which DocGo may purchase up to $36 million of its common stock during a 6-month period ending July 30, 2024. DocGo's prior share repurchase authorization expired on November 24, 2023. The approved amount represents approximately 10% of DocGo's outstandi.

DocGo Announces Share Buyback Program

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of DocGo Inc. (“DocGo” or the “Company”) (NASDAQ: DCGO) investors concerning the Company's possible violations of federal securities laws. On January 10, 2024, before market hours, Fuzzy Panda Research published a report alleging, among other things, that DocGo has been committing “systematic billing fraud” by forging signatures on documents, editing patient records to maximize profits, and billi.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DocGo Inc. (DCGO) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of DocGo Inc. (“DocGo” or the “Company”) (NASDAQ: DCGO) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your DocGo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DocGo Inc. (DCGO) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of DocGo Inc. (“DocGo” or the “Company”) (NASDAQ: DCGO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 10, 2024, before market hours, Fuzzy Panda Research published a report alleging, among other things, that DocGo has been committing “systematic billing fraud” by forging sig.

The Law Offices of Frank R. Cruz Announces Investigation of DocGo Inc. (DCGO) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--DocGo Provides Additional Information to Refute Misleading Short Seller “Report”.

DocGo Provides Additional Information to Refute Misleading Short Seller “Report”

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DocGo Inc. (NASDAQ: DCGO) (“DocGo”). On January 10, 2024, before the market opened, market analyst Fuzzy Panda released a report on DocGo titled, “DocGo – Allegations of Fraudulent Billing Practices & Forging of Documents.” Specifically, Fuzzy Panda found that “through former employee inte.

DCGO Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims Against DocGo Inc. (NASDAQ: DCGO)

NEW YORK , Jan. 11, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of DocGo Inc. (NASDAQ: DCGO) resulting from allegations that DocGo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased DocGo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DocGo Inc. Investors to Inquire About Securities Class Action Investigation - DCGO

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (“DocGo” or the “Company”) categorically rejects this purported assessment by Fuzzy Panda Research, an obscure short seller motivated solely by profit. Their so-called “research report” uses what appears to be old, public information to present an overall picture of DocGo and its business that is false, misleading and defamatory, and we intend to issue a cease-and-desist letter to the firm and are exploring all available legal means to respond. We believe t.

DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance

Shares of DocGo (NASDAQ: DCGO ), a company known for its mobile medical services, are plunging lower following the publication of a short report by Fuzzy Panda. The short seller has accused the company of improper billing practices, a management team with connections to fraud and unethical practices and contract issues in regards to New York City migrant asylum seekers, among other allegations.

Fuzzy Panda Slams DocGo (DCGO) Stock in New Short Report

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of DocGo Inc. (NASDAQ: DCGO) resulting from allegations that DocGo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased DocGo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen La.

DCGO LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages DocGo Inc. Investors to Inquire About Securities Class Action Investigation – DCGO

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled mobile health services, today announced that its medical staffing division that services federal agencies achieved the coveted ISO 9001:2015 certification. This Quality Management Systems (“QMS”) standard sets the bar for quality assurance, emphasizing continuous improvement, customer satisfaction, and efficient processes. This certification represents a significant milestone, demonstrating.

DocGo Subsidiary Achieves ISO 9001:2015 Certification, Further Elevating its Commitment to Quality Management

DocGo Chief Executive Lee Bienstock is standing by the mobile-healthcare company's performance under a controversial migrant-care contract awarded by New York City.

DocGo CEO Defends Performance on New York City Migrant-Care Contract

LOS ANGELES , Dec. 26, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DocGo Inc. ("DocGo" or the "Company") (NASDAQ: DCGO). Class Period: November 8, 2022 – September 17, 2023 Lead Plaintiff Deadline: December 26, 2023 If you wish to serve as lead plaintiff of the DocGo lawsuit, you can submit your contact information at www.glancylaw.com/cases/DocGo-Inc/.

News for DocGo Stock (DCGO)